Neratinib extended DFS in adjuvant treatment of breast cancer

  • July 25, 2014

Puma Biotechnology Inc. recently announced that its investigational drug for the extended adjuvant treatment of breast cancer met its primary endpoint in a phase 3 ExteNET trial.

The ExteNET trial is a double-blind, placebo-controlled trial of neratinib (PB272, Puma Biotechnology) vs. placebo after adjuvant treatment with trastuzumab (Herceptin, Genentech) among 2,821 women with early-stage HER-2–positive breast cancer.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
More»
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today